| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Ainos, Inc.$1.33
-0.03 (-2.21%)
D 35Pipeline Score Overvalued Biotech · Clinical
Market Cap
20.12 M
EPS
-2.90
P/E Ratio
-0.81 $
Value Trade
108.26 K
SEC Financials
Q1 2026Dilution Risk
Revenue
161.00
R&D Expenses
1.69 M
Operating CF
-983.42 K
Total Assets
22.08 M
Total Liabilities
16.39 M
Equity
5.69 M
D/E Ratio
12,345
0.49 %
Week
17.39 %
1 Month
41.62 %
3 Month
47.39 %
6 Month
-95.18 %
5 Year
-99.99 %
All Time
Cash Data
Cash Position
2.84 M
Monthly Burn
328.00 K
Runway
6.2 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
19.35 K
52 Week Range
1.26 - 4.50
% held by Insiders
75.2 %
% held by Institutions
1.69 %
Enterprise Value
31.09 M
Total Shares
4.82 M
Short %
5.66 %
Float Shares
250.74 K
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ainos, Inc.
107Total events
0Upcoming
28Tier-1 (high impact)
2020 – 2026Coverage
Event history 2
TBD
◆Full ResultsVELDONAFiledClinical Data
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D35
Pipeline Score $7M
Pipeline ValueOvervalued
Valuation Signal4
Drugs Scored0.4x
rNPV / MCap Top 51%
Micro Cap (rank 448 of 913)
Percentile RankAinos, Inc. faces pipeline headwinds (35/100), with $1.2B risk-adjusted pipeline value, led by Interferon alpha lozenge in Respiratory Tract Diseases (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interferon alpha lozenge Small molecule | Respiratory Tract Diseases | Phase 2 | NCT01442779 | 14% | $511M | COMPLETED | 18 | - | - | May 1, 2007 | - | Apr 20, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AIMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AIMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AIMDAinos Reports First Quarter 2026 Financial Results and Highlights Smell AI Execution Across Semiconductors and Healthcare Infrastructure Markets HOUSTON, TX / ACCESS Newswire /
Ainos, Inc. (NASDAQ:AIMD) reported its financial results for the first quarter of 2026, highlighting advancements in its AI Nose technology for semiconductor and healthcare infrastructure applications. The company has shifted focus from validation to more extensive deployments, showing strong operational milestones. A financing arrangement has enhanced their balance sheet, while a notable reduction in operating expenses showcases improved efficiency. The company is optimistic about future commercialization and revenue opportunities as it continues to expand its Smell ID datasets and refine its AI-driven solutions.
Read more →AIMDAinos Reports Full Year 2025 Financial Results and Highlights Commercial Momentum Entering 2026 AI Nose drove 499% revenue growth in 2025, with gross margin turning positive to 82.9% 2025 partnerships now driving scaled
Ainos, Inc. reported a substantial 499% revenue growth for 2025, driven by its AI Nose platform. The company has successfully transitioned its focus from healthcare to industrial applications, with deployments already beginning in semiconductor environments. Gross margins improved significantly to 82.9%, reflecting operational discipline. Ainos anticipates further growth in 2026, supported by early-stage implementations and effective partnerships. However, the company faces ongoing risks related to profitability and market competition.
Read more →AIMD▼ -9.8%on this news· ran to -23% by day 1
Ainos Reports Third Quarter 2025 Financial Results Digital olfactory commercialization accelerates toward 2026 scale-up, as industrial partnerships expand to six and the IP moat strengthens. World's first patented commer
Ainos, Inc. reported its financial results for Q3 2025, highlighting significant progress in its olfactory commercialization efforts as it gears up for a major scale-up in 2026. The company has successfully added six strategic partnerships in the semiconductor and industrial edge AI sectors, facilitating the deployment of its AI Nose technology. Additionally, Ainos launched the world's first patented AI Nose device, enhancing its competitive edge in the growing electronic-nose market. Its disciplined financial management has led to a notable decline in operational expenses, supporting its commercial strategies and expansion plans.
Read more →AIMDAinos Reports Second Quarter 2025 Financial Results 1H 2025 Kicks Off AI Nose's Growing Commercial Momentum with First Senior Care Revenue and New Strategic Partnerships AI Nose 90-Day Roadmap to Power 2H 2025, With Firs
Ainos, Inc. has reported strong financial results for the second quarter of 2025, highlighting the successful transition of its AI Nose platform from research and development to revenue-generating activities. The company secured significant collaboration agreements, including a $2.1 million subscription order with ASE Technology for semiconductor applications. Ainos is also gaining momentum in the senior care sector, having achieved its first commercial revenues in this space. The company's strategic roadmap outlines ambitious plans for scaling operations and expanding its market reach in various industries by the end of 2025.
Read more →AIMD▲ +39.9%on this news
Ainos Secures $2.1 Million Order With ASE for First Deployment of AI Nose in Semiconductor Manufacturing Setting First Revenue-Generating Milestone for AI Nose Smell Language Model in High-Value Industrial Applications A
Ainos, Inc. has announced a significant milestone by securing a $2.1 million subscription order with ASE Technology Holding Co. for the deployment of its AI Nose platform in semiconductor manufacturing. This order includes the deployment of 1,400 AI Nose units across three major manufacturing sites in Taiwan and represents Ainos' first revenue-generating success in high-value industrial applications. The company is also planning further deployments in Japan, aiming to strengthen its presence in the Asian market and enhance smart manufacturing with its innovative scent digitization technology.
Read more →AIMDAinos Regains Nasdaq Compliance, Sets 90-Day Roadmap to Scale AI Nose Platform in 2026 Commercial Momentum Accelerates with Partnerships to Drive AI-Powered Scent Intelligence for IndustrialAI and HealthcareAI SAN DIEGO,
Ainos Inc. (NASDAQ:AIMD) has announced its return to compliance with Nasdaq’s minimum bid price requirement, enabling its continued presence on the exchange. The company is focusing on scaling its AI Nose platform with a 90-day roadmap, aiming for large-scale commercialization by 2026. Partnerships with major firms like ASE Technology Holding are central to this growth, alongside achieving significant revenue increases. However, challenges such as future profitability and competition in the market are acknowledged as risks to the company's ambitious plans.
Read more →AIMDAinos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia AI Nose and SLM SmellTech platform enter scale-up phase targeting robotics, automation, and environment
Ainos, Inc. has partnered with Kenmec Mechanical Engineering to deploy AI-powered scent intelligence in smart factories across Asia. This strategic partnership aims to integrate Ainos' AI Nose and Smell Language Model into Kenmec's automation solutions, enhancing real-time environmental diagnostics in various sectors including logistics and healthcare. Both companies plan to showcase their technology jointly at Automation Taipei 2025. The collaboration is expected to accelerate growth in the emerging digital scent technology market.
Read more →AIMDAinos Reports First Quarter 2025 Financial Results Q1 revenues increased 412% year over year, driven by AI Nose products Delivers strong turnaround from gross loss to gross profit in Q1 AI Nose gains traction beyond heal
Ainos, Inc. reported a remarkable 412% increase in revenues for Q1 2025, primarily due to its AI Nose products, marking a turnaround to gross profit from a previous loss. The company is leveraging strategic partnerships in robotics and semiconductors to broaden the application of its technology, enhancing its market position. Additionally, Ainos received crucial approvals for two clinical trials in Taiwan, focusing on developing innovative therapeutics targeting specific health issues. This strong financial performance reflects early traction and a strategic shift aimed at long-term growth.
Read more →AIMDAinos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing Harnessing AI-Powered Scent Digitization for Smarter, Safer, and More Sustainable Factories SAN DIEGO, CA / ACCESS Newswire /
Ainos, Inc. has announced a partnership with Advanced Semiconductor Engineering (ASE) to implement AI-powered scent digitization in semiconductor manufacturing. This collaboration aims to enhance operational efficiency, environmental safety, and compliance with ESG regulations using patented AI Nose technology. The AI Nose, originally designed for healthcare applications, will now be utilized for monitoring airborne chemicals and optimizing manufacturing processes. The partnership represents a significant expansion of Ainos' product offerings and positions both companies at the forefront of innovation in smart manufacturing.
Read more →AIMDAinos Reports Full Year 2024 Financial Results Unveiled revolutionary AI Nose for robotics application, inviting global robotics companies to join Ainos Alliance in shaping the future of smell-enabled robots Advanced VEL
Ainos, Inc. announced its financial results for 2024, highlighting a strategic transition from COVID-19 products to advancements in AI Nose technology and the VELDONA drug development pipeline. The AI Nose program, particularly the Ainos Flora device, has shown promising accuracy and aims for commercialization soon. Despite reporting a decrease in revenues and a negative gross profit, Ainos is focused on expanding its product offerings and strategic partnerships to drive future growth. The company also made progress in its drug development for Sjögren's syndrome and animal health initiatives.
Read more →AIMDAinos and ugo to Develop the World's First Robot with a Sense of Smell A Major Breakthrough in Ainos' Mission to Digitize Scent First-ever Smell-Enabled Robotics Will Unlock New Revenue Streams in Smart Manufacturing, Pu
Ainos, Inc. and ugo, Inc. have announced a strategic partnership aimed at developing the world's first robotic systems equipped with olfactory perception through Ainos' AI Nose technology. This collaboration will enhance the capabilities of ugo's robots, allowing them to perform crucial tasks in industrial safety, public health, and security by detecting volatile organic compounds. The deployment of this technology is positioned to address labor shortages across various sectors by improving operational efficiency and workplace safety. The project represents a significant advancement in the integration of artificial intelligence with traditional robotics.
Read more →AIMD▼ -8.3%on this news
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sj gren's Syndrome Drug San Diego, California-(Newsfile Corp.
Ainos, Inc. has announced a strategic partnership with Taiwan Tanabe Seiyaku to advance the manufacturing and market promotion of its drug VELDONA for Sjögren's syndrome. The collaboration aims to address the significant demand for effective treatments in this area. VELDONA is a low-dose oral interferon-alpha that has shown promising results in clinical trials, indicating potential to improve patient symptoms and quality of life. The partnership is expected to facilitate a quicker market introduction of the drug, meeting a pressing healthcare need.
Read more →AIMDAinos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety
Ainos, Inc. has announced a breakthrough with its AI Nose technology, achieving 79% accuracy in identifying volatile organic compounds in semiconductor manufacturing. This advancement allows for real-time detection of harmful gas leaks and enhances worker safety in smart factories. The AI Nose aims to be integrated into robotic systems, allowing for better monitoring and response to hazardous conditions. This innovation is expected to significantly improve safety and efficiency in industrial operations.
Read more →AIMD▼ -17.1%on this news
Ainos Reports Second Quarter 2024 Financial Results Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developments Robust financial runway for over 12 months f
Ainos, Inc. has reported its second quarter 2024 financial results, highlighting progress in its clinical study for the treatment of feline chronic gingivostomatitis (FCGS). The company has successfully enrolled its first subject and anticipates completing the trial by early 2025. Despite achieving a robust financial runway for more than 12 months following recent financing, Ainos experienced a decline in revenues due to the cessation of COVID-19 product sales and rising operational costs. Their strategy remains centered on the commercialization of low-dose interferon therapeutics and expanding into the animal health market.
Read more →AIMD▲ +7.3%on this news
Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA Clinical trials for AI Nose-powered Ainos Flora device moves forward with 75 meaningful case results, paving the wa
Ainos, Inc. has announced significant progress in clinical trials for its Ainos Flora device, which utilizes AI technology for point-of-care testing of infections. The trials have reported 75 meaningful case results, demonstrating the device's potential in non-invasive testing. The company plans to leverage NVIDIA CUDA for improvements in their next-generation device, expected to begin trials by Q4. This innovation targets decentralized healthcare solutions, particularly in home testing for STIs and vaginal health.
Read more →AIMDAinos Reports First Quarter 2024 Financial Results Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing gr
Ainos, Inc. reported its financial results for Q1 2024, highlighting a strategic pivot away from COVID-19 rapid tests, which has impacted revenue. The company secured US$9 million in growth capital to bolster its financial position, facilitating the advancement of its AI-powered point-of-care testing and drug candidates for HIV. Despite a significant drop in first-quarter revenues compared to the previous year, Ainos continues to diversify its business strategy to enhance long-term sustainability. Operating expenses have increased due to rising costs in clinical trials and staffing.
Read more →AIMD▲ +83%on this news
Ainos Reports Full Year 2023 Financial Results Strategic pivot towards VELDONA and AI-powered point-of-care testing to continue in 2024 Advancing VELDONA drug candidates to Phase III clinical studies Expanding market of
Ainos, a diversified healthcare company, reported its financial results for 2023, highlighting a strategic pivot toward VELDONA and AI-powered point-of-care testing. The company's revenues fell significantly due to decreased demand for COVID-19 test kits, leading to a negative gross profit. Despite these challenges, Ainos has made promising advances, including moving VELDONA drug candidates to Phase III trials and achieving positive outcomes in clinical studies for its treatment targeting oral warts in HIV-positive patients. The firm aims to diversify its revenue streams and enhance its product offerings in 2024.
Read more →AIMDAinos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms Updated Chemistry, Manufacturing, a
Ainos, Inc. has submitted a clinical hold complete response to the U.S. FDA regarding its VELDONA formulation aimed at treating mild COVID-19 symptoms. This response addresses previously identified deficiencies, paving the way for a Phase II trial expected in Taiwan later in 2024. The company's progress includes the manufacturing of a compliant GMP Clinical Batch, and optimism surrounds VELDONA's potential effectiveness against mild COVID-19. Ainos plans to submit additional IND applications for different health conditions in the near future.
Read more →AIMDAinos, Inc. to Present at Small-Cap Growth Virtual Investor Conference February 7th
Ainos, Inc. announced that Jack Lu, the Director of Corporate Development, will present at the Small-Cap Growth Virtual Investor Conference on February 7, 2024. The presentation will allow real-time interaction with investors, along with opportunities for one-on-one meetings. Ainos is a healthcare company focused on innovative testing and therapeutics, expanding its portfolio including low-dose interferon and COVID-19 point-of-care tests. Archived webcasts will be available for those unable to attend the live event.
Read more →AIMDAinos , Inc. Announces Stock Consolidation
Ainos, Inc. has announced a reverse stock split, consolidating five shares into one, effective December 14, 2023. This action aims to manage the company's share structure and may improve its market position. The number of outstanding shares will reduce to approximately 4.68 million, while the company's ticker symbol will remain the same. Ainos focuses on developing point-of-care testing and therapeutics but faces challenges due to financial constraints and market dependence on specific products.
Read more →AIMDAinos Reports Third Quarter 2023 Financial Results Product Cycle Transition Approaches its Final Stages
Ainos, Inc. reported its third quarter 2023 financial results, showcasing efforts to pivot from COVID-19 related products to new revenue streams. The successful launch of VELDONA Pet supplements in Taiwan is a key highlight. However, the company faced a decrease in revenue due to diminished demand for COVID-19 test kits, resulting in negative gross profit. Additionally, the company reported a net loss, although expenses have decreased significantly. Future prospects include advancing their AI-powered point-of-care testing and drug candidates.
Read more →AIMDPROMISSORY NOTE EXTENSION AGREEMENT This Promissory Note Agreement (the "Agreement") is entered into this 17 th day of August, 2023 (the "Effective Date") by and between Ainos, Inc., a Texas corporation (the "Maker"), an
Ainos, Inc. has entered into a promissory note extension agreement with i2China Management Group, LLC. The agreement extends the maturity date of a previously established non-convertible promissory note for $84,000, which had an unpaid principal of $42,000. This extension allows for a new maturity date of September 1, 2024. In addition, terms for prepayment of the note are preserved under this agreement.
Read more →AIMDAinos Reports Second Quarter 2023 Financial Results Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered Testing Launch of VELDONA Pet Provides New Revenue Stream for Near-Term; Ainos Flora Remains
Ainos, Inc. reported its financial results for Q2 2023, revealing a significant decline in revenue due to the reduced demand for COVID-19 products. The company is shifting its strategic focus from COVID to capitalize on opportunities in the growing pet health market, launching its VELDONA Pet supplement line and making progress with its Ainos Flora testing device. Despite the new initiatives, Ainos continues to face financial challenges, with increased net losses and operational expenses. The company aims to achieve a target of US$20 million in sales for the VELDONA Pet line in 2024.
Read more →AIMD▼ -6.5%on this newsshared move
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform For Broader Industry Adoption The Collaboration Signals Era of New Innovation for AI Nose Technology for Broader Industry Adoptio
Ainos, Inc. has partnered with Nisshinbo Micro Devices and Inabata to co-develop a volatile organic compound (VOC) sensing platform aimed at broader industry applications, including telehealth and environmental safety. This collaboration signifies a step forward in Ainos' mission to innovate with its AI Nose technology, which is protected by numerous patents. The project is designed to enhance VOC detection capabilities, utilizing advanced AI algorithms and big data analysis. Ainos aims to expand its market potential while addressing health and environmental concerns associated with VOCs.
Read more →AIMD▼ -5.1%on this news
Ainos Appoints Amanda Sung as New Chief Financial Officer Current CFO Celia Wu announces her retirement and transition to consulting role Sung brings nearly two decades of public company audit and compliance experience w
Ainos, Inc. has announced the appointment of Amanda Sung as its new Chief Financial Officer, effective May 17, 2023. She succeeds Celia Wu, who is retiring but will continue to contribute in a consulting role. Sung brings nearly two decades of experience in public company audit and compliance, particularly within the healthcare sector, which could benefit Ainos as it continues to innovate in medical technology.
Read more →AIMD▲ +5.9%on this news· ran to +129% by day 3
Ainos Announces US$3 Million Convertible Notes Private Placement SAN DIEGO, CA / ACCESSWIRE /
Ainos, Inc. has announced a private placement of $3 million in convertible notes, which will mature in two years and bear an interest rate of 6% per annum. The notes can be converted into common shares at a price of $1.50 each. This move is expected to enhance Ainos' financial stability and support the advancement of its product pipeline. The company plans to provide further details in a Form 8-K with the SEC, highlighting its commitment to transparency in the investment process.
Read more →AIMDAinos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split SAN DIEGO, CA / ACCESSWIRE /
PRICING PRESS RELEASE aimd_ex991.htm EXHIBIT 99.1 Ainos Announces Pricing of $3.3 Million Public Offering, Uplisting to NASDAQ, and Reverse Stock Split SAN DIEGO, CA / ACCESSWIRE / August 8, 2022 / Ainos, Inc. (OTC PINK:AIMD) ("Ainos", or the "Company"), a diversified medtech
Read more →AIMDAinos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection SAN DIEGO, CA / ACCESSWIRE /
aimd_ex991.htm EXHIBIT 99.1 Ainos Announces Strategic Relationship with InnoPharmax to Jointly Develop Combined Oral Therapy for Coronavirus Infection SAN DIEGO, CA / ACCESSWIRE / December 7, 2021 / Ainos, Inc. ("we", "our", or the "company"), (OTC PINK: AIMD), a diversified he
Read more →AIMDAinos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key Executives Monday
Ainos Elects Ms. Hui-Lan (Celia) Wu as CFO, Lawrence K. Lin as Executive Vice President of Operations, and Other Key SAN DIEGO, CA / ACCESSWIRE / August 16, 2021 / Ainos, Inc. ("we", "our", or the "Company"), (OTC PINK:AIMD), elected Ms. Hui-Lan (Celia) Wu as its new Chief Fi
Read more →AIMDAinos Announces FINRA Approval of Name Change and Ticker Symbol Change to “AIMD”, Engages Firm to Explore Listing Requirements of National Securities Exchanges San Diego, CA
Ainos Announces FINRA Approval of Name Change and Ticker Symbol Change to AIMD , Engages Firm to Explore Listing Requirements of National Securities Diego, CA, May 24, 2021 Ainos, Inc., f/k/a Amarillo Biosciences, Inc. Company ), (OTCPK: AIMD), is pleased to announce that th
Read more →AIMDAmarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to “Ainos, Inc.” Amarillo, TX
Amarillo Biosciences, Inc. Announced Closing under Securities Purchase Agreement with Majority Investor and Name Change to TX, April 21, 2021 Ainos, Inc., f/k/a Amarillo Biosciences, Inc. ( we or the Company ), (OTCBB: AMAR), a company engaged in the discovery and development
Read more →AIMDAmarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Growth
Amarillo Biosciences, Inc. Enters into a Securities Purchase Agreement to Foster New Amarillo, TX, December 30, 2020 -- Amarillo Biosciences, Inc. ( we , ABI or the Company ), (OTCBB: AMAR), a company engaged in low-dose non-injectable interferon research, announced today th
Read more →Competitive Position
How AIMD ranks across every disease it competes inCompetitive Position is a premium feature
See how AIMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial